Medivation briefly popped Wednesday after reports that at least five pharmaceutical companies expressed interest in buying it.
David Sowerby, Loomis Sayles & Co. vice president, and Steven Dudash, IHT Wealth Management president, share stocks they think can soar 50 percent or more over the next year.
Just buying the biggest share repurchasers doesn't seem to be working anymore. Here's what investors might want to do instead.
Stock buybacks aren't juicing share prices the way they once did, so it pays to be selective, according to UBS.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
Ronny Gal, Sanford C. Bernstein, discusses the potential of a takeover deal for Biogen.
The "Fast Money" traders said on Tuesday that mergers and acquisitions may help the biotechnology sector hit new highs.
The "Fast Money" traders discuss their views on Biogen.
The Fast Monet Trader's discuss the surge in Biogen after talk of a possible buyout.
CVS Health's new "excluded" list includes medications used in treatment of patients with cancer, diabetes and hepatitis C.
A judge ruled that an HIV pill to prevent infection could be funded by the U.K.'s state health service, in a victory for AIDS campaigners.
Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.
CNBC's Mike Santoli discusses why this year could be called the "year of the value trap."
CNBC Senior Markets Commentator Mike Santoli explains how the market has imposed a high cost on the owners of "cheap" stocks this year.
AbbVie's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.
Verizon, Anheuser-Busch and Gilead Sciences are making headlines this morning before the opening bell.
Some of the names on the move ahead of the open.
Gilead Sciences lowered its full-year sales outlook, citing slower-than-expected demand for its hepatitis C drugs, and said profits fell 22 percent.